Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-20507 single ascending dose study in healthy adults
ACTRN12623000709640Phase 2Completed
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2 trial of BW-20507 in Chronic Hepatitis B (CHB), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of a single dose of BW-20507. Started Aug 2023; status: completed.
02
Drugs
BW-20507
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12623000709640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000709640.